TP53 and central nervous system cancer: Generally, 91% glioma samples harbored IDH1 mutation, which mostly concurrent with either TP53 and ATRX mutations in astrocytoma samples or with CIC and FUBP1 mutations in oligodendroglioma samples in CYT-low cohort.